Oncology

News

Could your loyalty card help spot cancer? Study says yes

A study by UK researchers has found that buying patterns for over-the-counter (OTC) medicines for pain and indigestion, recorded using a store loyalty card, could be used to pick up early s

News

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

News

Jazz swings on ASCO-GI data for zanidatamab

Jazz Pharma's $325 million gamble on rights to Zymeworks' HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout

News

ASCO-GI data sets up wider use of Ipsen's Onivyde

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023

News

Takeda grabs ex-China fruquintinib rights from Hutchmed

Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of

Could your loyalty card help spot cancer? Study says yes

EU clears Enhertu for HER2-low breast cancer

Merck's Keytruda flunks another prostate cancer test

Jazz swings on ASCO-GI data for zanidatamab

ASCO-GI data sets up wider use of Ipsen's Onivyde

Takeda grabs ex-China fruquintinib rights from Hutchmed

On addressing drug waste and ensuring access, with Jeff Harp...

How to meet your physicians where they are online

Oncology

Editor's Picks